ESMO 2025

Rethinking dosing in TNBC

Refining the standard treatments for early breast…

Confirmative OS data on CDK4/6 inibitors for pts with…

Toward a new standard - T-DXd in early breast cancer

Financial toxicity

New insights into PROTAC SERD vepdegestrant

Exciting news for young patients who want to get…

T-DXd neoadjuvant improves pCR

First time OS - confirming clinical practice

POSITIVE trial - update

Optimizing G-CSF administration helps reducing side…

T-DXd right from the start – in a neoadjuvant situation…

Durvalumab improves OS in TNBC

Adjuvant data with CDK4/6 inhibitors in HR+ breast…

Individual consultation remains important

T-DXd in high-risk patients in the postneoadjuvant…

CDK4/6 inhibitors – confirmed effect

The first neoadjuvant therapy decreases chemotherapy in…

Great update for young women

OS-benefit with abemaciclib

Optimal timepoint of G-CSF administration after…

A first step into a great story

Ki67 after preoperative chemotherapy - a new strong…

Un primer paso hacia una gran historia

La primera terapia neoadyuvante reduce la quimioterapia…

Momento óptimo para la administración de G-CSF después…

Prima valutazione della OS: conferma della pratica…

monarchE OS

Ki67 po przedoperacyjnej chemioterapii - nowy istotny…

Future perspectives for firstline therapy

Future perspectives on TNBC therapy

Practice changing data for firstline TNBC

Combination matters

Transforming TNBC

ADC, the first

Gedatolisib in patients with PI3K wild type HR+ mBC

Survival data from SONIA

Meeting the unmet need in advanced TNBC not eligible…

Breakthroughs for high-risk patients

Early positioning of third-generation ADCs in treatment

TROP2 ADC, the second

Reforming destiny

ADCs are coming for first line TNBC

Stronger together

Another good option for patients with mTNBC

Changing the paradigm of treatment in 1L of TNBC

Should this drug be available outside of China?

TROP2 number 3

Gli ADC si fanno strada nella prima linea del TNBC

Gedatolisib chez les patients atteints d'un cancer du…

La combinazione conta

Gedatolisib in pazienti con mBC HR+ PI3K wild type

Otra buena opción para pacientes con mTNBC

Cambiando el paradigma del tratamiento en la primera…

Nowa szansa dla chorych na zaawansowanego, potrójnie…

Positionnement plus précoce des ADCs de troisième…

Navigating ALK TKI choices in ALK+ NSCLC

Immunotherapy and biomarkers in resectable NSCLC:…

A bridge to surgery

New chances for locally advanced NSCLC

FLAURA2: OS outcomes in poor-prognosis EGFRm NSCLC with…

ALEX: Long-term OS benefit with Alectinib in ALK+ NSCLC

NorthStar: Osimertinib ± local therapy in EGFR-mutant…

Therapy sequencing after EGFR-TKI progression: insights…

Eradication of all disease - is this the true north?

The added value of radiotherapy in EGFR mutated NSCLC

New treatment options for HER2-mutation positive NSCLC

Sac-TMT now also available for NSCLC

EGFR exon 20 - What does the future hold?

Is this the end for pembrolizumab?

Ivonescimab in NSCLC - a new SOC?

The return of antiangiogenic strategy in squamous NSCLC

Treat your BRAF-patients in 1L

Save and effective - Ivonescimab in HARMONi-6

New kid on the block for EGFRm

Sac-TMT - a potential new option for EGFRm NSCLC…

Update for pts with BRAF mutation

Local therapy in addition to osimertinib 1st line in…

New prospect for squamous tumors

New options after EGFR-TKI failure

Local ablative therapy in EGFR-mutated NSCLC

HER2 altered - small population, many options

ALK - longterm

Is chemo-IO an option if you want a rapid response in…

sac-TMT a new SOC

Two is better than one

Anti-TROP-2 ADCS - new data in EGFRm NSCLC

New chances for locally advanced NSCLC

NorthStar - new navigation principle

Alectinib remains a potential SOC

Due è meglio di uno

ADCS anti-TROP-2 - nouvelles données sur le EGFRm NSCLC

È la fine per Pembrolizumab?

De toegevoegde waarde van radiotherapie bij…

Le retour de la stratégie antiangiogénique dans le…

Nuevas perspectivas para los tumores escamosos

New kid on the block for EGFRm

Molecular factors and ctDNA dynamics linked to outcomes…

Prognostic role of exosomes in stage IIIA(N2) NSCLC…

T-cell engager in 1st line SCLC

Bending the gravity of SCLC

Tarlatamab combination in 1st line SCLC

Dramatic improvement of PFS in 1L treatment

DLL3 targeting drugs moving to frontline therapy

Amélioration spectaculaire de la survie sans…

Zal tarlatamab de eerstelijnsbehandeling van…

The hippo-pathway in Mesothelioma

Adding to the adjuvant RCC story - how do we move…

Another part of the puzzle

Further intensification of therapy with potential…

Input for the second line in ccRCC

The dawn of molecular imaging in renal cell carcinoma

Adjuvans in high risk RCC after surgery

Relevance of CPI neoadjuvant and adjuvant

More evidence in second-line treatment for metastatic…

Therapy-relevant aspects for first-line treatment of…

MIBC: Practice Changing data towards bladder…

UTUC: Impressive PFS und OS Benefit with Disitamab…

NMIBC: Making the right choice for high risk patients!

Negative, but important data to discuss

A well-tolerated and effective new neoadjuvant concept…

Adding checkpoint inhibitor in high risk NMIBC shows…

A newcomer in advanced urothelial cancer

Perioperative and adjuvant standards for MIBC

Neoadjuvant HER2-targeted therapy for kidney-sparing…

When precision matters, the case of ctDNA in mIBC

Bladder cancer highlights from ESMO 2025

Is ICI to BCG suitable for NMIBC?

Too early for primetime

De-escalation promotes a better QoL while maintaining…

The ADC story continues

New options for neoadjuvant therapy in MIBC

Therapy intensification in patients ineligible for…

Better QoL for patients with metastatic bladder cancer

Dose modifications, new combinations, new substances in…

ADC Enfortumab vedotin + Pembrolizumab in MIBC

Neoadjuvant combination of local and systemic therapy…

A highly selective FGFR3 inhibitor for first-line…

Setting the bar even higher in mIBC

Elevando aún más el estándar en mIBC

Données négatives, mais importantes à discuter

Cuando la precisión importa: el caso de ctDNA en mIBC

Κύρια σημεία για τον καρκίνο της ουροδόχου κύστης από…

Is this the new standard of care?

Docetaxel vs. Lutetium in chemosensitive mCRPC

Impressive OS-data from EMBARK

The role of lutetium in mHSPC – is its use clinically…

Practice-changing data for mHSPC

Final OS results for EMBARK

Example for biomarker guided precision medicine in…

Changed chemo-regimen leads to less toxicity in mHSPC

OS-benefit in BCR

New docetaxel regimen in combination with darolutamide…

Ändrad kemoterapiregim leder till mindre toxicitet vid…

Imponerande OS-data från EMBARK